 LAVAL, QC, and CAMBRIDGE, England, Dec. 15, 2020 PRNewswire - Liminal BioSciences Inc. Nasdaq: LMNL Liminal BioSciences or the Company, a clinical-stage biopharmaceutical company, today announced that the first subject has been dosed in the Companys fezagepras Phase 1 multiple... 